Abstract 2834: BH3 profiling predicts clinical response in a phase II clinical trial of ABT-199 (GDC-0199) in acute myeloid leukemia
暂无分享，去创建一个
A. Keating | A. Letai | M. Konopleva | D. DeAngelo | I. Galinsky | R. Stone | J. Leverson | R. Humerickhouse | J. Ricker | G. W. Foight | B. Chyla | J. Potluri | M. Mabry | N. Falotico | L. Hogdal | E. Mckeegan